HuMab Company Review
The HuMab business model aims to generate revenue by licensing out its authentic and original antibody platform technology to pharmaceuticals. The fees include the upfront fee, running loyalty, and milestone fees. These drugs produce synthetic antibodies that target antigens by invigorating the human immune system. The medicines are medically tested and approved by the respective authority. The technology used to create the antibody-drug is phage display and transgenic mouse. The only vision of HuMab is to utilize the intellectual property rights of Synthese.
Technologies Used By HuMab.:
The latest technologies used by HuMab are:
- Antibody Platform Technology: This technology produces specific antibodies from human genes instead of humanizing the animal-based antibody.
- Fully Humanized Antibody Technology: This technology is represented by Phage Display and Transgenic Mouse. The phage display is a gene combination method that allows human to artificially produce actual antibody through the natural immune system. The transgenic mouse uses the combination method to discover new drug candidates.
- AICE Technology: AICE is the acronym to Artificial Interspecies Chromosome exchange that induces chromosome level replacement by recombination enzyme. After getting inserted at both ends, it generates a human cell to microcell and fuse with mouse cells. Thus finally, it encourages replacement.
Don't use plagiarised sources.Get your custom essay just from $11/page
Products ByHuMab:
The four new antibody drugs have been planned to be launched by HuMab. The field targeted is Cancer immunotherapy and immune disorder treatment via transgenic mouse platform. The targeted drugs should contain at least one antibody-drug with clinical effectiveness to target the antigen. The cancer immunotherapies are emerging as a new paradigm for cancer cure. The immunotherapies are beneficial as they produce minimum side effects as compared to 1st gen chemotherapy and 2nd gen target theory. The immune disorder treatment is targeting atopic dermatitis and inflammatory bowel disease. Thus HuMab has to be innovative to capture the target markets.
Strategies Used By HuMab:
- Positioning Best In Class: Under this strategy, the drug test is done for original, and biosimilar drugs, a drug that is approved first is called first in class, while the drug that is best in quality and efficiency is called best in class.
- Strategic Alliance: Under this strategy, HuMab aims to network with global pharmaceutical companies under which parties engage in a joint development process. HuMab benefits from the alliance as it can focus more on the discovery of antibody drug candidates.
- Roadmap To Growth: Three phases form part of growth. The first phase is to prove the competitiveness of HuMab; the second phase is to prove the economic value, and third and the final phase is to become a global biopharma.
Thus, HuMab for successful implementation intends to operate a well -defined organizational structure. The CEO of the company leads the Life Science Research Institute And Management Support Division at Seoul Bio Hub, Korea. The respective R&D team will manage the R&D projects and tasks that have been allotted to the entire institute. The R&D management team will look into the work done by R&D teams. Hence effective implementation of strategies is possible only when the team has practical support.